
GHRS Stock Forecast & Price Target
GHRS Analyst Ratings
Bulls say
GH Research is on track to potentially revolutionize the treatment of depression, with a strong focus on their proprietary inhalable and injectable mebufotenin products. Their recent financial results have demonstrated increasing cash reserves, providing strategic support for their planned end-of-phase 2 regulatory alignment and Phase 3 initiation and execution. The company has also garnered positive attention in the medical community with peer-reviewed publications and ongoing medical meeting presence, which further reinforces the potential of their lead product, GH001, in treating TRD.
Bears say
GH Research is still in the early stages of development and their portfolio currently consists of only two products. However, the results from their Phase 2b trial and the additional funding they received in April ($378 million) support their potential to be a major player in the psychiatry field as they work towards introducing transformative psychedelic therapies. Despite this, GH Research is keeping details of their proprietary aerosolized device and dosing regimen confidential for competitive reasons, which may hinder investor confidence and limit their success in the long term.
This aggregate rating is based on analysts' research of GH Research PLC and is not a guaranteed prediction by Public.com or investment advice.
GHRS Analyst Forecast & Price Prediction
Start investing in GHRS
Order type
Buy in
Order amount
Est. shares
0 shares